Why is contrast-enhanced CT preferred over fluorodeoxyglucose PET-CT for initial staging of cholangiocarcinoma?

Why CECT is Preferred Over FDG PET-CT for Initial Staging of Cholangiocarcinoma

Contrast-enhanced CT (CECT) is preferred over FDG PET-CT for initial staging of extrahepatic cholangiocarcinoma because CECT provides superior anatomic detail for assessing vascular involvement (hepatic artery and portal vein), determining resectability, and evaluating the longitudinal extent of disease—all critical factors that directly impact surgical planning and patient outcomes. 1

The Guideline-Based Rationale

The 2025 EASL guidelines explicitly state that multiphasic contrast-enhanced thorax-abdomen-pelvis CT should be used to assess hepatic artery and portal vein involvement and to look for distant metastases 1. In stark contrast, the same guidelines provide a strong recommendation that FDG-PET should NOT be used for the diagnosis and local staging of extrahepatic cholangiocarcinoma 1. This represents the highest level of guideline evidence against using PET-CT as a primary staging tool.

Why CECT Excels for Initial Staging

Vascular Assessment is Critical for Resectability

• CECT demonstrates 89% sensitivity and 92% specificity for portal vein involvement, and 83% sensitivity and 93% specificity for hepatic artery involvement 2
• Vascular invasion determines whether curative resection is possible—the only treatment that improves 5-year survival
• PET-CT provides metabolic information but lacks the spatial resolution to accurately map vascular anatomy and tumor-vessel relationships

Anatomic Detail Drives Surgical Planning

• CECT achieves 86% accuracy for evaluating ductal extent of tumor 2, which is essential for determining the appropriate surgical approach
• The Bismuth-Corlette classification system used to guide surgical resection relies on precise anatomic mapping that only cross-sectional imaging can provide
• Contrast MRI with MRCP complements CT by analyzing bile duct anatomy and longitudinal tumor extent 1

The Limitations of FDG PET-CT in Cholangiocarcinoma

Poor Sensitivity for Primary Tumor Detection

Research demonstrates that FDG PET-CT detected primary tumors in only 60% of extrahepatic cholangiocarcinoma patients, compared to 80% detection by CT 3. This is particularly problematic for:

• Infiltrating growth patterns that are common in perihilar cholangiocarcinoma 4
• Mucinous subtypes which show low FDG avidity 4
• Small lesions where metabolic activity may not exceed background 5

Inadequate for Regional Lymph Node Staging

While PET-CT shows high specificity (100%) for lymph node metastases, its sensitivity is only 38% 5, meaning it misses the majority of involved regional nodes. This is inferior to CT's 54% sensitivity 3, though both modalities have limitations. The 2023 EASL-ILCA guidelines recommend EUS-guided fine needle aspiration for lymph node sampling when results would alter management 6, not PET-CT.

False Positives from Inflammation

A critical pitfall: cholangiocarcinoma patients frequently have biliary stents and pre-existing inflammation, which cause false-positive FDG uptake 1. The FDA label for FDG explicitly warns that inflammatory processes give rise to false-positive examinations 7. This is particularly problematic in cholangiocarcinoma where biliary obstruction and cholangitis are common.

When PET-CT Has Value (But Not for Initial Staging)

The evidence shows PET-CT's role is complementary, not primary:

• For intrahepatic cholangiocarcinoma (not extrahepatic), PET-CT helps identify occult lymph node and distant metastases in apparently resectable disease 6
• High specificity (95-97%) for distant metastases makes it useful for detecting unsuspected metastatic disease 6, 4
• Prognostic value: SUVmax ≥5 predicts poor survival and increased metastatic risk 5

However, these benefits do not translate to initial staging of extrahepatic cholangiocarcinoma, where anatomic assessment drives management decisions.

The Clinical Algorithm

For initial staging of extrahepatic cholangiocarcinoma:

1. Perform staging BEFORE biliary stent placement to avoid inflammatory false positives 1
2. Start with multiphasic CECT of thorax-abdomen-pelvis to assess:
   • Vascular involvement (portal vein, hepatic artery)
   • Distant metastases
   • Resectability
3. Add contrast MRI with MRCP to evaluate:
   • Bile duct anatomy
   • Longitudinal tumor extent
4. Use EUS with fine needle aspiration for suspicious lymph nodes when confirmation would change management 1
5. Reserve PET-CT for problem-solving in select cases, not routine staging

Common Pitfalls to Avoid

• Do not rely on PET-CT alone for staging decisions—its low sensitivity for primary tumors and regional nodes will lead to understaging
• Do not interpret post-stent FDG uptake as malignancy—inflammation causes false positives
• Do not use PET-CT to determine resectability—it lacks the anatomic precision needed for vascular assessment
• Do not skip CECT in favor of PET-CT—you will miss critical anatomic details that determine surgical approach

The evidence is clear: CECT provides the anatomic roadmap necessary for surgical planning and resectability assessment, while FDG PET-CT's metabolic information adds little value to initial staging and carries significant risk of false positives in this inflammatory disease context.